| Literature DB >> 24790598 |
Folasoge A Adeyankinnu1, Babatunde O Motayo1, Akinniyi Akinduti2, John Akinbo1, Joseph I Ogiogwa1, Bukola W Aboderin1, R A Agunlejika3.
Abstract
As a result of the ever increasing problem of multiresistant bacteria, we instituted a surveillance program with the aim of identifying the basic molecular properties of ESBL in our environment. About 197 isolates of Escherichia coli and Klebsiella pneumoniae were selected and tested for ESBL production and antimicrobial susceptibility. Plasmid profiles were determined and curing ability was tested. ESBL prevalence was 26.4% for all isolates tested, with E. coli having a greater proportion. There was absolute resistance to ampicilin, tetracycline, and co-trimaxole among tested isolates. There was above average susceptibility to the 2nd and 3rd generation cephalosporins. Plasmid profiles of tested isolates ranged from 9 kbp to 26 kbp with average of 14.99 ± 2.3 kbp for E. coli and 20.98 ± 1.8 kbp K. pneumoniae, 9.6% of ESBL positive E. coli plasmids were cured, while 3.9% of K. pneumoniae plasmids were cured after treatment. The present study shows an upsurge in ESBL acquisition by gram negative bacteria and evidence of cocirculation of varying subtypes of ESBL with both plasmid transmissible and chromosome encoded subtypes. This calls for universal surveillance and more effort towards molecular epidemiology of this public health treatment.Entities:
Year: 2014 PMID: 24790598 PMCID: PMC3982411 DOI: 10.1155/2014/819896
Source DB: PubMed Journal: Interdiscip Perspect Infect Dis ISSN: 1687-708X
Figure 2Agarose gel electrophoresis of plasmid DNA after curing.
Figure 1Culture plate showing synergy of clavulanic acid containing disk with ceftazidime in the double disk synergy test (DDST) for ESBL detection. A is augmentin + ceftazidime. B is ceftazidime alone. Zone of inhibition of A − zone of inhibition of B ≤ 5 mm; it is ESBL negative. Zone of inhibition of A − zone of inhibition of B ≥ 5 mm; it is ESBL positive.
Frequency of isolates (n = 197) in relation to sites.
| Study site |
|
| ||
|---|---|---|---|---|
| Number of isolates | Percentage (%) | Number of isolates | Percentage (%) | |
| F.M.C | 67 | 49.7 | 30 | 48.4 |
| Ijaiye | 50 | 37.0 | 22 | 35.5 |
| Lantoro | 18 | 13.3 | 10 | 16.1 |
|
| ||||
| Total | 135 | 100 | 62 | 100 |
Frequency rate of ESBL positive E. coli and Klebsiella pneumoniae in various clinical samples.
| Samples | Number of isolates | ESBL positive isolates | |||
|---|---|---|---|---|---|
|
|
| ||||
| Number ( | Percentage (%) | Number ( | Percentage (%) | ||
| Blood | 26 ( | 6 | 3.0 | 2 | 1.0 |
| Urine | 73 | 14 | 7.1 | 5 | 2.5 |
| CSF | 9 ( | 0 | 0 | 0 | 0 |
| Semen | 3 | 0 | 0 | 0 | 0 |
| Endocervical | 9 | 4 | 2.0 | 0 | 0 |
| HVS | 4 | 0 | 0 | 0 | 0 |
| Catheter | 9 | 2 | 1.0 | 0 | 0 |
| Sputum | 12 | 0 | 0 | 4 | 2.0 |
| Ear swab | 12 ( | 4 | 2.0 | 0 | 0 |
| Wound | 20 | 2 | 1.0 | 0 | 0 |
| Pus | 8 | 2 | 1.0 | 2 | 1.0 |
| Pleural fluid | 12 | 2 | 1.0 | 3 | 1.5 |
|
| |||||
| Total | 197 ( | 36 | 18.3 | 16 | 8.1 |
NB: *Isolates recovered from pediatric subjects.
Antibiotic susceptibility rate of ESBL isolates obtained from different clinical samples to commonly used antibiotics by disc diffusion test.
| Antibiotic |
|
| |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (ug/disc) |
| % |
| % |
| % |
| % |
| % |
| % | |
| AMP | 10 | 0 | 0 | 0 | 0 | 36 | 100 | 0 | 0 | 0 | 0 | 16 | 100 |
| OFLX | 5 | 16 | 44.4 | 2 | 5.6 | 18 | 50 | 6 | 37.5 | 4 | 25 | 06 | 37.5 |
| AUG | 20/10 | 9 | 25 | 2 | 5.6 | 25 | 69 | 4 | 25 | 2 | 12.5 | 10 | 63 |
| COT | 5/25 | 0 | 0 | 0 | 0 | 36 | 100 | 0 | 0 | 0 | 0 | 16 | 100 |
| GEN | 5 | 13 | 36.1 | 4 | 11.1 | 19 | 54 | 5 | 31.2 | 1 | 6.3 | 10 | 63 |
| NIT | 30 | 20 | 55.6 | 5 | 13.9 | 09 | 25 | 8 | 50 | 2 | 12.5 | 06 | 37.5 |
| TET | 30 | 0 | 0 | 0 | 0 | 36 | 100 | 0 | 0 | 0 | 0 | 16 | 100 |
| CAZ | 10 | 3 | 8.3 | 3 | 8.3 | 30 | 83 | 4 | 25 | 2 | 12.5 | 10 | 63 |
| CRO | 10 | 5 | 13.9 | 3 | 8.3 | 28 | 78 | 5 | 31.2 | 3 | 18.8 | 08 | 50 |
| CXM | 10 | 1 | 2.8 | 3 | 8.3 | 32 | 89 | 0 | 0 | 4 | 25 | 12 | 75 |
| IMP | 5 | 36 | 100 | 0 | 0 | 0 | 0 | 16 | 100 | 0 | 0 | 0 | 0 |
R-plasmid profile of ESBL positive Escherichia coli and pneumonia among the clinical samples.
| Clinical samples | Average plasmid size (kbp) | |
|---|---|---|
|
|
| |
| Blood | 14.6 | 19.9 |
| Urine | 15.8 | 21.7 |
| CSF | 0 | 0 |
| Semen | 0 | 0 |
| ECS | 13.8 | 0 |
| HVS | 0 | 0 |
| Catheter | 24.3 | 0 |
| Sputum | 0 | 22.1 |
| Ear | 13.0 | 0 |
| Wound | 17.0 | 0 |
| Pus | 10.3 | 21.2 |
| Pleural fluid | 11.1 | 20.0 |
| Average weight | 20.71 ± 2.3 | 25.10 ± 1.8 |
Plasmid curing rate for the ESBL positive E. coli and K. pneumoniae.
| Number of isolates with plasmid | Number of isolates with no plasmid after curing | Percentage of isolates cured (%) | |
|---|---|---|---|
|
| 36 | 5 | 9.6 |
|
| 16 | 2 | 3.9 |
|
| |||
| Total | 52 | 7 | 13.5 |